Navigation Links
New Drugs No Better Than Older Ones for Schizophrenia

However, patients stay on the new medications longer, study finds

FRIDAY, March 28 (HealthDay News) -- Newer, so-called second-generation antipsychotics are no better than the older drug haloperidol in treating a first episode of schizophrenia, a new study finds.

However, it appears that more patients prefer the newer drugs and are more likely to continue using them than haloperidol, the study authors said.

"When we compared newer drugs to older drugs, we found that patients stay longer on the new drugs," said lead researcher Dr. Rene Kahn, a professor of psychiatry at the University Medical Centre Utrecht in the Netherlands.

Earlier studies had found 70 percent of schizophrenia patients stopped taking the older antipsychotics. In the new study, 70 percent of patients kept with the newer drugs, Khan noted.

"The biggest reason that they stayed longer was that doctors perceived the newer drugs as more efficacious," Khan said. "That's the way real life is -- real life is that patients and doctors perceive their medication to have a certain efficacy."

But, if you look at improvement in symptoms and the number of times patients were hospitalized after the first treatment, then the drugs did not differ, Khan said.

The findings are published in the March 29 issue of The Lancet.

Kahn's team randomly assigned 498 patients to haloperidol, or higher-dose second-generation drugs that included amisulpride, olanzapine, quetiapine and ziprasidone.

Over the following year, 63 patients discontinued haloperidol, compared with 32 who stopped using amisulpride, 30 who stopped using olanzapine, 51 who quit quetiapine and 31 who stopped taking ziprasidone, the researchers found.

However, regardless of which medication the patients were taking, 60 percent saw a reduction in their symptoms, the researchers found. And, when the researchers looked at gender, and side effects such as suicidal behavior and substance abuse, they didn't find any significant difference among the drugs.

The hopeful sign is that patients taking the newer drugs stayed on them longer, Khan said.

"Overall, we should be encouraged that if we give the patients the right drug, that in 60 to 70 percent of the cases, they still stay on the medication," Khan said. "We should not be so pessimistic, as earlier studies suggested, that we cannot treat schizophrenia because only 30 percent of the patients stayed on the drug."

Dr. Robert A Rosenheck, a professor of psychiatry at Yale University School of Medicine and author of an accompanying editorial in the journal, said the only way to test whether patients prefer the newer drugs to the older ones is to have an objective trial in which patients and doctors don't know who's getting which drug.

"In terms of the main outcome of how long patients stayed on their drugs, the study showed a benefit for the newer drugs," he said. But, since the doctors knew which drugs were being given, the study results likely reflected the doctors' opinions of the drugs, he added.

The study began in 2002, Rosenheck noted, when there was a lot of enthusiasm for these new drugs. "The assumption of many doctors was, 'I want my patients on newer drugs as soon as possible,' " he said.

"The only way you get an objective assessment is by doing a study in which you can be sure neither the patient nor the physician knows which drug it is. So, they are just judging by the clinical outcomes. That's the standard for evaluating drugs," Rosenheck said.

More information

For more on schizophrenia, visit the U.S. National Institute of Mental Health.

SOURCES: Rene Kahn, M.D., Ph.D., professor of psychiatry, University Medical Centre, Utrecht, the Netherlands; Robert A. Rosenheck, M.D., professor of psychiatry, Yale University School of Medicine, New Haven, Conn.; March 29, 2008, The Lancet

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs
2. Increasing access to antiretroviral drugs would drastically cut AIDS deaths in South Africa
3. Drugs Approved Under Deadline More Likely to Run Into Trouble Later
4. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
5. PCMA: Independent Drugstore Lobbys Prompt Pay Agenda Could Cost Medicare $3.3 Billion Over the Next Decade
6. China Nepstar Chain Drugstore Announces Dividend
7. Significant Generic Erosion Will Cause Sales of Dyslipidemia Drugs to Decline by $3.6 Billion by 2016
8. China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007
9. Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility
10. Wal-Mart Saves Customers More Than $1 Billion On Prescription Drugs
11. FDA Panel Supports Anemia Drugs for Cancer Patients
Post Your Comments:
Related Image:
New Drugs No Better Than Older Ones for Schizophrenia
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
Breaking Medicine Technology: